In this image of Alzheimer’s brain tissue, gingipains from the bacteria P. gingivalis are red; MAP2, a marker of neurons, is yellow; and GFAP, a marker of glial cells surrounding neurons, is green.
by Sharon Begley, August 13, 2019
While large pharmaceutical companies have been reporting failure after expensive failure in their efforts to develop an Alzheimer’s drug by targeting amyloid, a growing number of startups have been quietly trying different strategies. One approach, pioneered by South San Francisco-based Cortexyme, is based on an old idea that is gaining traction after being shunted aside for decades: that an infectious agent causes Alzheimer’s, and that targeting that pathogen and the neuronal havoc it wreaks can stop and even reverse some aspects of the disease. Read more